A Pilot Study on the Comparative Efficacy and Tolerability of a Novel Dermo-cosmetic Cream with 15% Azelaic Acid for Mild to Moderate Acne: A New Approach to Acne Treatment Authors: Aura Vladuti, Afshin Hatami, Amélie Clément, Carine Mainzer Published: 2024 ABSTRACT IntroductionAcne is a one of the most frequent skin conditions among teenagers and young adults. It is currently managed with topical retinoids and antibiotics, which can present numerous side effects, thus reducing treatment adherence and effectiveness. We evaluated the efficacy and tolerability of a novel dermo-cosmetic cream (α-AZ) in treating mild to moderate acne.MethodsSubjects were randomized into three groups: group 1 received α-AZ cream, group 2 was treated with α-AZ combined with an oral acne treatment routine, and group 3 received a topical acne treatment, for 84 days. All treated patients underwent a 28-day maintenance period with α-AZ cream. Total acne and post-inflammatory hyperpigmentation (PIH) scoring, quality of life (QoL), and skin tolerance were all evaluated during the treatment and maintenance periods.ResultsAcne and PIH lesions significantly decreased in group 1 compared to group 3 (p < 0.001), with a reduction in acne of 66.52 ± 2.92% in group 1 versus 52.55 ± 3.90% in group 3. Patients in group 1 achieved nearly clear skin by the end of the treatment. α-AZ cream treatment was well tolerated and all participants experienced an enhanced QoL. Participants expressed high satisfaction. Additional enhancements in all groups were noted during the maintenance phase across all clinical parameters.ConclusionThe novel dermo-cosmetic α-AZ cream could serve as a valuable new approach to current treatments for mild and moderate acne. It can be used alone, as a once-daily adjuvant to oral acne treatments, or as part of a maintenance regimen.Trial registrationISRCTN registry, ISRCTN70142596, registered retrospectively on 11/12/2023. Key Summary Points Acne vulgaris is a prevalent skin condition, especially among teenagers and young adults. Traditional treatments, including topical retinoids and antibiotics, often lead to side effects that reduce adherence and effectiveness. Additionally, the rise of antibiotic resistance presents a significant challenge, creating an unmet need for effective alternatives.The study aimed to evaluate the efficacy and tolerability of a novel dermo-cosmetic cream containing 15% azelaic acid (α-AZ) in alleviating acne burden in patients with mild to moderate acne.The α-AZ cream alone or in combination significantly reduced acne severity compared to a topical antibiotic treatment. The cream was well tolerated, improved the quality of life, and demonstrated effectiveness as a standalone treatment and in combination therapy.The study suggests that the novel α-AZ cream could be a promising new approach for treating mild to moderate acne, especially given its high tolerability and effectiveness in reducing PIH. The latter is one of the most impactful sequelae affecting the quality of life for patients with acne, as it persists even after the inflammation has resolved. This could shift treatment practices towards using more dermo-cosmetic formulations, offering effective alternatives that improve patient outcomes and reduce side effects. Acne vulgaris is a prevalent skin condition, especially among teenagers and young adults. Traditional treatments, including topical retinoids and antibiotics, often lead to side effects that reduce adherence and effectiveness. Additionally, the rise of antibiotic resistance presents a significant challenge, creating an unmet need for effective alternatives.The study aimed to evaluate the efficacy and tolerability of a novel dermo-cosmetic cream containing 15% azelaic acid (α-AZ) in alleviating acne burden in patients with mild to moderate acne.The α-AZ cream alone or in combination significantly reduced acne severity compared to a topical antibiotic treatment. The cream was well tolerated, improved the quality of life, and demonstrated effectiveness as a standalone treatment and in combination therapy.The study suggests that the novel α-AZ cream could be a promising new approach for treating mild to moderate acne, especially given its high tolerability and effectiveness in reducing PIH. The latter is one of the most impactful sequelae affecting the quality of life for patients with acne, as it persists even after the inflammation has resolved. This could shift treatment practices towards using more dermo-cosmetic formulations, offering effective alternatives that improve patient outcomes and reduce side effects. Introduction Acne vulgaris, commonly referred to as acne, is undoubtedly the most prevalent skin condition observed among adolescents and young adults, with a worldwide prevalence of 20.5% [1]. In some cases, acne may persist into adulthood. It is a chronic, inflammatory, multifactorial skin disease mainly observed on the face, neck, chest, and upper back, where pilosebaceous units are predominant [2]. The development of acne vulgaris involves the overproduction and modification of the lipid composition of sebum in sebaceous glands, the hyperkeratinization of follicular epidermis, and dysbiosis as well as the inflammation of the sebaceous gland caused by the hyperproliferation of Cutibacterium acne [3, 4]. Clinically, both non-inflammatory and inflammatory lesions are observed. The latter may ultimately evolve into either atrophic scars, post-inflammatory erythema (PIE), or hyperpigmentation (PIH) [2]. In addition to physical lesions, acne may cause depression, anxiety, and low self-esteem [5]. The treatment of acne comprises a combination of approaches tailored to the severity and type of condition. These may include topical treatments (benzoyl peroxide (BPO), retinoids) and oral medications such as antibiotics (erythromycin, clindamycin, doxycycline) and isotretinoin [6–8]. Nevertheless, all these treatments have safety concerns, particularly topical retinoids or BPO, which can cause irritation [9]. Additionally, the primary issue with antibiotic use is the development of resistance, which may reduce their effectiveness in treating acne [10]. Azelaic acid (AZ), with its antibacterial activity and comedolytic effect, is recognized as one of the most effective compounds, showing efficacy comparable to other approved treatments [11, 12]. However, current formulations with AZ, as solo agent, may cause itching, dryness, and irritation [13]. This study aimed to evaluate the efficacy and tolerability of a novel dermo-cosmetic α-AZ cream (Teen Derm® A.Z cream, ISISPHARMA, France) when used alone or in combination with oral antibiotics for the treatment of mild to moderate acne. This cream consists of 15% AZ combined with a proprietary mixture of avocado oil ester, glycerol, and xylitol, as well as natural extracts of Boswellia serrata (α-pure complex). Formulated to address sebum regulation, inflammation, and hydration dysregulation commonly associated with acne, it has also demonstrated a reduction in the adherence of C. acnes on the skin surface in vitro [14–16]. Methods Study Design and Subjects This study is an open-label, randomized, comparative, parallel group clinical study (ISRCTN70142596). Patients with mild to moderate acne were recruited from two investigational sites in Romania between October 2022 and June 2023. This study complied with good clinical practices and the principles of the Declaration of Helsinki. All participating subjects or their caregivers provided written informed consent prior to inclusion. Subjects comprised girls or boys, aged 12 years and older, with mild to moderate acne. According to the Global Evaluation of Acne (GEA) scale, subjects with grade 2 acne had a few comedones, papules, and pustules (score < 5), while those with grade 3 acne had many comedones, papules, and pustules (5 < score < 9), with the possible presence of one nodule. Those who had received a combination of a retinoid and BPO, orally administered isotretinoin, or who regularly used anti-inflammatory drugs prior to the study were excluded. Individuals who had used hormonal treatment in the 3 months preceding the study were also excluded. Those with excessive exposure to sunlight or UV rays within the previous month were not enrolled in this study. A total of 90 subjects were equally randomized into three groups: group 1 (α-AZ, n = 30) received α-AZ cream, applied twice daily; group 2 (α-AZ/oRC (oral routine care), n = 30) was treated with α-AZ cream in combination with orally administered doxycycline (100 mg) with each treatment given once daily; and group 3 (tRC (topical routine care), n = 30) received a fixed combination of erythromycin 40 g/mL and zinc 12 mg/mL applied topically twice daily. All subjects were instructed to use a gel cleanser (Teen Derm® Gel cleanser, ISISPHARMA, France) twice daily alongside their acne care regimen. Patient follow-ups were scheduled during the 84-day treatment period for a total of three visits (baseline (D0), day 42 (D42), and day 84 (D84)). Following the treatment period, all groups received α-AZ cream twice daily for an additional 28 days (D112, end of maintenance phase). It should be noted that since one patient from group 2 did not complete the maintenance period they were completely excluded from the analysis (Fig. 1).Fig. 1Study design and treatment plan. A total of 90 subjects were equally randomized into three groups: group 1 (α-AZ) received α-AZ cream applied twice daily, group 2 (α-AZ/oRC) was treated with α-AZ cream in combination with orally administered doxycycline (100 mg) with each treatment given once daily, and group 3 (tRC) received a fixed combination of erythromycin 40 g/mL and zinc 12 mg/mL twice daily, during 84 days. Clinical evaluation was assessed at baseline, day 42 (D42), D84, and D112 (end of maintenance period) Study design and treatment plan. A total of 90 subjects were equally randomized into three groups: group 1 (α-AZ) received α-AZ cream applied twice daily, group 2 (α-AZ/oRC) was treated with α-AZ cream in combination with orally administered doxycycline (100 mg) with each treatment given once daily, and group 3 (tRC) received a fixed combination of erythromycin 40 g/mL and zinc 12 mg/mL twice daily, during 84 days. Clinical evaluation was assessed at baseline, day 42 (D42), D84, and D112 (end of maintenance period) Clinical Outcome Assessments Efficacy evaluations were conducted at baseline and at each study visit to assess acne severity, using the ECLA scale as described by Dreno et al. [17]. Counting of acne lesions included open and closed comedones, papules, pustules, and nodules (Table 1), followed by the calculation of the total acne score. The total number of PIH marks (red and brown marks) was also obtained following the same ECLA scale where scores ≤ 2 indicate none, scores between 3 and 4 indicate mild, scores between 5 and 6 indicate moderate, and scores between 7 and 8 indicate severe PIH. The relative changes from baseline (%) were calculated for both parameters. Moreover, investigators evaluated patient tolerability by documenting erythema, edema, dryness, desquamation, and roughness. Subjects completed a quality of life (QoL) questionnaire (Cardiff Acne Disability Index, CADI) [18] at D0 and D84. At D42 and D84, subjects in group 1 or 2 completed the questionnaire on the effectiveness and cosmetic acceptability of the product.Table 1Acne grading systemRNone< 55–910–1920–40> 40 Open or closed comedons (microcysts)R = 0R = 1R = 2R = 3R = 4R = 5IsNone< 55–910–1920–40> 40 Papules and pustulesIs = 0Is = 1Is = 2Is = 3Is = 4Is = 5IpNone12345 or more Nodules and inflammatory cystsIp = 0Ip = 1Ip = 2Ip = 3Ip = 4Ip = 5Total acne score = R + Is + Ip Table 1Acne grading systemRNone< 55–910–1920–40> 40 Open or closed comedons (microcysts)R = 0R = 1R = 2R = 3R = 4R = 5IsNone< 55–910–1920–40> 40 Papules and pustulesIs = 0Is = 1Is = 2Is = 3Is = 4Is = 5IpNone12345 or more Nodules and inflammatory cystsIp = 0Ip = 1Ip = 2Ip = 3Ip = 4Ip = 5Total acne score = R + Is + Ip Acne grading system Color photographs of the full face and right and left profiles were taken of patients on D0, D42, and D84 using a Fotofinder Medicam 800 and Sometech Dermatoscop with Samsung Camera OIS F1.8. Statistical Analysis Statistical analyses were performed using SAS 9.4 software (SAS Institute Inc., Cary, NC, USA.). Quantitative variables were expressed as mean ± SEM. Scores were presented at each visit, as well as changes between visits and relative changes (%). Between-group comparisons were performed using the Wilcoxon two-sample test: group 1 versus group 3, group 2 versus group 3, and group 1 versus group 2. Within-group comparisons were performed using the Wilcoxon signed rank test. Statistical tests were performed at the two-sided 5% significance level. Results A total of 90 subjects were enrolled in the study. One patient withdrew from group 2 before completing the maintenance period. Subjects were predominantly female (80.0%) with a mean age of 22.1 ± 7.0 years. The main phototype was phototype III (82.0%); none of the subjects had phototype I, V, or VI. The GEA score was 2 in 42.7% of the subjects and 3 in 57.3%. The mean total number of acne lesions at baseline was 6.5 ± 2.0 (corresponding to mild acne) and the mean PIH score was 6.9 ± 1.2 (moderate PIH). The mean CADI score at baseline was 8.7 ± 3.9 (moderate effect of acne on the patient’s life). Detailed demographic and baseline data per treatment group and overall are given in Table 2.Table 2Patient demographics and baseline characteristicsGroup 1 (α-AZ)N = 30Group 2 (α-AZ/oRC)N = 29Group 3 (tRC)N = 30Study populationN = 89Gender Male6 (20.0%)7 (24.1%)5 (16.7%)18 (20.2%) Female24 (80.0%)23 (75.9%)25 (83.3%)72 (79.8%)Age (years) Mean (SD)22.3 ± 6.121.7 ± 8.622.3 ± 6.322.1 ± 7.0 Median (range)20.5 (14–33)19.0 (7–46)21.0 (14–40)21.0 (7–46)Phototypea II4 (13.3%)6 (20.7%)5 (16.7%)15 (16.9%) III26 (86.7%)22 (75.9%)25 (83.3%)73 (82.0%) IV0 (0.0%)1 (3.4%)0 (0.0%)1 (1.1%)GEA grade 217 (56.7%)7 (24.1%)14 (46.7%)38 (42.7%) 313 (43.3%)22 (75.9%)16 (53.3%)51 (57.3%)Total acne score Mean (SD)6.0 ± 1.57.3 ± 2.26.2 ± 2.26.5 ± 2.0 Median (range)6.0 (4–9)7.0 (4–15)6.0 (3–13)6.0 (3–15)PIH total score Mean (SD)6.8 ± 1.37.4 ± 0.86.6 ± 1.36.9 ± 1.2 Median (range)7.0 (4–8)8.0 (6–8)7.0 (4–8)7.0 (4–8)CADI score Mean (SD)8.1 ± 3.310.5 ± 3.67.6 ± 4.38.7 ± 3.9 Median (range)8.0 (0–13)11.0 (3–15)7.5 (0–15)9.0 (0–15)GEA Global Evaluation of Acne, PIH post-inflammatory hyperpigmentation, CADI Cardiff Acne Disability IndexaParticipants with phototype I, V, and VI were not present in this study Table 2Patient demographics and baseline characteristicsGroup 1 (α-AZ)N = 30Group 2 (α-AZ/oRC)N = 29Group 3 (tRC)N = 30Study populationN = 89Gender Male6 (20.0%)7 (24.1%)5 (16.7%)18 (20.2%) Female24 (80.0%)23 (75.9%)25 (83.3%)72 (79.8%)Age (years) Mean (SD)22.3 ± 6.121.7 ± 8.622.3 ± 6.322.1 ± 7.0 Median (range)20.5 (14–33)19.0 (7–46)21.0 (14–40)21.0 (7–46)Phototypea II4 (13.3%)6 (20.7%)5 (16.7%)15 (16.9%) III26 (86.7%)22 (75.9%)25 (83.3%)73 (82.0%) IV0 (0.0%)1 (3.4%)0 (0.0%)1 (1.1%)GEA grade 217 (56.7%)7 (24.1%)14 (46.7%)38 (42.7%) 313 (43.3%)22 (75.9%)16 (53.3%)51 (57.3%)Total acne score Mean (SD)6.0 ± 1.57.3 ± 2.26.2 ± 2.26.5 ± 2.0 Median (range)6.0 (4–9)7.0 (4–15)6.0 (3–13)6.0 (3–15)PIH total score Mean (SD)6.8 ± 1.37.4 ± 0.86.6 ± 1.36.9 ± 1.2 Median (range)7.0 (4–8)8.0 (6–8)7.0 (4–8)7.0 (4–8)CADI score Mean (SD)8.1 ± 3.310.5 ± 3.67.6 ± 4.38.7 ± 3.9 Median (range)8.0 (0–13)11.0 (3–15)7.5 (0–15)9.0 (0–15)GEA Global Evaluation of Acne, PIH post-inflammatory hyperpigmentation, CADI Cardiff Acne Disability IndexaParticipants with phototype I, V, and VI were not present in this study Patient demographics and baseline characteristics GEA Global Evaluation of Acne, PIH post-inflammatory hyperpigmentation, CADI Cardiff Acne Disability Index aParticipants with phototype I, V, and VI were not present in this study Clinical Efficacy Evaluation Total Acne Scores Total acne score, which provides a holistic view of overall acne severity by integrating all types of lesions, and relative changes from baseline were calculated and are shown in Fig. 2. All groups exhibited mild acne at baseline, with a total average acne score of 6.5 ± 0.36, with group 2 having the highest score (p < 0.05) (Fig. 2a). Treatment with α-AZ cream alone (group 1) or in combination with orally administered doxycycline (group 2) as well as topical antibiotic treatment alone (group 3) led to a significant reduction in acne lesions, across all time points (p < 0.05 compared to baseline, Fig. 2a). Notably, group 1 showed the most significant improvement, achieving the lowest total acne score among the three groups. Specifically compared to group 3, with a total acne score of 2.9 ± 1.5, group 1 had a significantly lower total acne score of 2.00 ± 0.20 at D84 (p < 0.05), resulting in clear skin for patients by the end of the treatment (Fig. 2a). Group 2 also demonstrated a comparable decrease in total acne score reaching almost clear skin by the end of the treatment, with a score of 2.8 ± 0.19 (Fig. 2a). To account for potential differences in baseline acne severity between groups, we calculated the relative change, with results shown in Fig. 2b. A reduction of 66.52 ± 2.92% and 87.78 ± 2.58% at D84 and D112, respectively, was observed in the group 1 (Fig. 2b). Group 2 also showed a reduction of 61.43 ± 4.53% at D84, although to a lesser extent compared to group 1 (Fig. 2a, b). It is important to note that no significant difference was observed between group 1 and group 2, indicating that the combination therapy does not outperform the α-AZ cream alone in reducing acne lesions. In contrast, group 3 exhibited a reduction of only 52.55 ± 3.90% in acne score (p < 0.05, Fig. 2b). These findings suggest that treatment with α-AZ cream alone or in combination proved effective in reducing acne severity, specifically at D84.Fig. 2Total acne scores (a) and relative changes (%) from baseline (b) at different time points (D0, D42, D84, and D112) for groups 1, 2, and 3. *p < 0.05 and **p < 0.01 comparison between treatment. ##p < 0.01 vs group 3. Data are shown as mean ± SEM Total acne scores (a) and relative changes (%) from baseline (b) at different time points (D0, D42, D84, and D112) for groups 1, 2, and 3. *p < 0.05 and **p < 0.01 comparison between treatment. ##p < 0.01 vs group 3. Data are shown as mean ± SEM Total PIH Score Another clinical parameter was evaluated to assess the effectiveness of treatments. Total score and the mean relative changes from baseline (%) were calculated for all groups (Fig. 3). Figure 3a shows the total PIH score at various time points (baseline, D42, D84, and D112) for the three different treatment groups. Initially, patients presented moderate marks (mean scores of 7); however, as treatment progressed, the total PIH score significantly decreased across all groups with all patients exhibiting mild marks by the end of the treatment period (p < 0.05 compared to baseline). For instance, in group 2, the PIH score decreased from 7.40 ± 0.14 at baseline to 5.5 ± 0.28 at D84 (p < 0.05, Fig. 3a). Group 1 showed a more pronounced decrease in PIH total score (relative change) when compared to group 3, at the end of treatment (p < 0.05, Fig. 3b). At D84, group 1 showed a reduction of 44.89 ± 3.31% whereas group 3 only demonstrated a decrease in PIH marks of 27.83 ± 2.99% (p < 0.05, Fig. 3b). Interestingly, a significant decrease in PIH marks was observed in group 1 at the end of the maintenance period (D112) in comparison to groups 2 and 3. Group 1 demonstrated a decrease of 72.83 ± 4.51% whereas groups 2 and 3 showed reductions of 56.32 ± 5.73% and 56.61 ± 5.47%, respectively, at D112 (p < 0.05, Fig. 3b).Fig. 3a Post-inflammatory hyperpigmentation (PIH) lesion counting scores and b relative changes (%) from baseline curve, calculated for the three treated groups at various time points. *p < 0.05 indicates significant difference between groups.#p < 0.05 vs group 3. Significant results were observed compared to baseline for all treated groups. Data are presented as mean ± SEM a Post-inflammatory hyperpigmentation (PIH) lesion counting scores and b relative changes (%) from baseline curve, calculated for the three treated groups at various time points. *p < 0.05 indicates significant difference between groups.#p < 0.05 vs group 3. Significant results were observed compared to baseline for all treated groups. Data are presented as mean ± SEM Representative images displaying the faces of subjects in the three treated groups at baseline and D84 are represented in Fig. 4. Accordingly, these photos showed the improvements in acne among patients following treatment.Fig. 4Representative images showing the faces of subjects in the groups 1, 2, and 3 at D0 and D84. In each case, three views were taken: full face and right and left profiles using a digital camera (FotoFInder Medicam 800 and Sometech Dermatoscop with Samsung Camera OIS F1.8) Representative images showing the faces of subjects in the groups 1, 2, and 3 at D0 and D84. In each case, three views were taken: full face and right and left profiles using a digital camera (FotoFInder Medicam 800 and Sometech Dermatoscop with Samsung Camera OIS F1.8) Quality of Life (QoL) Figure 5 displays the total CADI score across all treatment groups and time points. At baseline, the total CADI score was significantly higher in group 2 compared to groups 1 and 3 (p < 0.05), with a total score of 10.51 ± 0.73 (Fig. 5). A significant decrease in the CADI score was observed in the three treated groups, indicating an amelioration of patient QoL (p < 0.05 compared to baseline). A reduction of 72.28 ± 4.10, 62.40 ± 4.01, and 59.20 ± 6.00% was observed in groups 1, 2 ,and 3, respectively, with the highest improvement seen in group 1 (data not shown). However, no significant difference was observed among different treatment groups (p > 0.05).Fig. 5Quality of life (QoL), as represented by the CADI score, was obtained for all treated groups at days 0 and 84. *p < 0.05, **p < 0.01 between treatment. Data are shown as mean ± SEM Quality of life (QoL), as represented by the CADI score, was obtained for all treated groups at days 0 and 84. *p < 0.05, **p < 0.01 between treatment. Data are shown as mean ± SEM Treatment Tolerance and Patient’s Assessment Treatment tolerance was evaluated at the end of the treatment period for all treated groups (data not shown). Across all visits, no treatment-related signs such as erythema, edema, dryness, desquamation, roughness, or any other adverse effects were reported, except for one patient in group 2 (α-AZ/oRC) who experienced moderate roughness at D84. Moreover, following 84 days of treatment with α-AZ alone or in combination with oRC, patients noted improvements in various aspects. They reported that their skin felt more comfortable, soothed, less irritated, clearer, purified, smoother, less greasy and sticky, less shiny, and better hydrated. Additionally, they observed a reduction in skin imperfections, inflammation, inflammatory lesions, and marks. Discussion The management of acne vulgaris comprises multiple treatment options, including topical or systemic approaches, which may be used either alone or in combination, to address the severity and clinical presentation of the condition. European recommendations advocate for strategies that target both inflammatory and non-inflammatory lesions, aiming to prevent scarring and minimize disease recurrence [19]. AZ has emerged as a highly effective therapeutic choice for acne vulgaris, showing comparable efficacy to other well-known treatments like tretinoin 0.5% cream, BPO 5% gel, and erythromycin 2% [20]. The multifaceted mechanism of action of AZ includes anti-inflammatory, antibacterial, comedolytic, and anti-keratinizing properties [21]. It also exerts anti-androgenic and anti-seborrheic effects [22]. All of these properties make AZ particularly suitable for acne management. AZ can be used either in monotherapy or in combination with other therapies. Additionally, it exhibits a better safety and tolerability profile compared to BPO, for instance [19]. However, adverse events may occur after AZ treatment such as burning, stinging, and pruritus [11, 23]. In this randomized clinical pilot study, we assessed the tolerability and efficacy of a novel AZ formulation based on 15% azelaic acid combined with a proprietary mixture of ingredients (α-AZ cream) in treating acne disease. The study aimed to assess the benefits of this dermo-cosmetic cream under real-life prescription conditions, without influencing with the investigators’ treatment choice. Consequently, various oral and pharmacological active acne treatments, including orally administered doxycycline and a topical formulation containing erythromycin, were prescribed by the investigators. α-AZ formulation led to a significant improvement in acne lesions at the end of the treatment period, compared to the topical antibiotic formulation, with no noticeable difference with the combination treatment. PIH is a significant pigmentary consequence of acne even in patients with mild to moderate acne. The inflammation process of acne, involving the release of inflammatory cytokines, likely contributes to PIH by increasing melanin production and causing its abnormal distribution [24]. As a result of their long-lasting nature, PIH has been shown to impact patient’s quality of life more than the acne itself [25]. The versatile biological properties of AZ, such as its antimicrobial activity, its ability to modify follicular epidermal hyperproliferation, to control inflammatory lesions and total lesions, and most importantly its anti-tyrosinase activity, likely contribute to its efficacy in treating PIH associated with mild to moderate acne [13, 21]. The results of this study showed that the treatment with the new dermo-cosmetic cream, containing AZ, was effective in reducing PIH marks compared to topical treatment by the end of the treatment and maintenance periods. Interestingly, the combined α-AZ and oral therapy demonstrated a similar tendency in reducing PIH marks as α-AZ treatment alone, although better results were obtained after the maintenance period for group 1. This could be explained by the fact that group 2 had more severe PIH at the beginning of the study compared to group 1. The persistence of inflammation may have interfered with the treatment’s ability to reduce pigmentation, as ongoing inflammation can trigger new hyperpigmentation, counteracting any progress made by the treatment. Given the resistant and relapsing nature of hyperpigmentation, treating PIH may require long-term treatment, and the duration of the study or treatment regimen might not have been sufficient to fully observe the potential effectiveness in resolving pigmentation. Despite this, patients treated with the combination therapy showed an improvement, shifting from severe to moderate PIH after treatment, which could be related to the presence of active complex ingredients alongside azelaic acid. Moreover, treatment with α-AZ also showed an enhancement in patient quality of life. These findings underscore the effectiveness of the novel dermo-cosmetic formulation in alleviating acne burden, in subjects with skin phototypes II and III. Moreover, the α-AZ cream demonstrated excellent safety and tolerability, with no reports of treatment-related adverse effects. This was primarily due to the presence of the α-pure complex ingredients. This contrasts with the potential side effects associated with antibiotics, which can include gastrointestinal disturbances, bacterial resistance development, and systemic effects [26]. Given the increasing number of prescriptions of antibiotics, even though they are not first-line treatments for acne, along with the use of concomitant topical agents and the variation in C. acnes strains, it is important to be cautious when prescribing antibiotics for acne treatment, as acne-prone skin is increasingly colonized by antibiotic-resistant C. acnes. This situation compromises the efficacy of antibiotic treatment, as it becomes challenging to eliminate the bacteria, potentially resulting in the emergence of additional resistant bacterial species [10, 27, 28]. Recently, Dréno et al. [29] underscored the significant role of microbial imbalance among non-pathogenic commensal strains such as C. acnes and Staphylococcus epidermidis in the inflammatory process of acne. They highlighted how this imbalance, combined with reduced diversity and stability among C. acnes phylotypes, contributes to the inflammation in acne. Additionally, it has been shown that antibiotics can also affect these non-pathogenic resident bacteria leading to the selection of resistant strains. This antimicrobial resistance and dysbiosis can further compromise the efficacy of antibiotics [30]. Consequently, the evaluated dermo-cosmetic cream could emerge as a good alternative to antibiotics or be included in a drug therapy regimen for addressing mild to moderate acne. On the other hand, it could offer a valuable treatment option for pregnant women, for whom the use of retinoids and antibacterial is currently contraindicated [31]. In addition to the product’s remarkable tolerability, patient self-assessments revealed improvements in various aspects of skin health and cosmetic acceptability including comfort, soothing, reduction of irritation, clarity, purification, smoothness, reduced greasiness, and improved hydration. This finding highlights the importance of well-adapted formulations in acne management, considering the common issue of low adherence to treatment due to side effects (erythema, dryness, and peeling), lack of understanding about acne and its treatment along with poor patient satisfaction [32, 33]. Moreover, the recurrence of acne after treatment is frequently observed, emphasizing the importance of implementing a maintenance phase to prevent relapses and enhance the treatment’s effectiveness. European guidelines recommend the use of anti-comedogenic agents such as AZ, BPO, and adapalene rather than topical or systemic antibiotics. For instance, a study conducted by Bettoli et al. [34] showed that a 12-month maintenance period with a combination of BPO and adapelene effectively managed acne and prevented relapses. Continuing treatment with α-AZ cream for an additional 28 days, as demonstrated here, further emphasized its efficacy and tolerability within a shorter time frame compared to existing literature data. One limitation of this study is that it did not include a group treated with retinoids, given that their mechanism of action is comparable to that of azelaic acid. Further comparative studies with larger sample sizes, other phototypes, and longer follow-up periods are necessary to validate these findings and establish the long-term efficacy and safety of α-AZ cream in the treatment of acne. Conclusion This study suggests that the dermo-cosmetic α-AZ cream, whether used alone or in combination with antibiotics, effectively treats acne while providing favorable safety and cosmetic benefits, making it a valuable option in the management of acne.